Next Article in Journal
Obesity and Cancer: 27-Hydroxycholesterol, the Missing Link
Next Article in Special Issue
Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy
Previous Article in Journal
Transcriptome and Hormone Analyses Revealed Insights into Hormonal and Vesicle Trafficking Regulation among Olea europaea Fruit Tissues in Late Development
Previous Article in Special Issue
High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy
Open AccessReview

Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(14), 4821; https://doi.org/10.3390/ijms21144821
Received: 15 June 2020 / Revised: 2 July 2020 / Accepted: 6 July 2020 / Published: 8 July 2020
(This article belongs to the Special Issue Adenovirus: Enduring Toolbox for Basic and Applied Research)
Non-human primate (NHP)-derived adenoviruses have formed a valuable alternative for the use of human adenoviruses in vaccine development and gene therapy strategies by virtue of the low seroprevalence of neutralizing immunity in the human population. The more recent use of several human adenoviruses as oncolytic agents has exhibited excellent safety profiles and firm evidence of clinical efficacy. This proffers the question whether NHP-derived adenoviruses could also be employed for viral oncolysis in human patients. While vaccine vectors are conventionally made as replication-defective vectors, in oncolytic applications replication-competent viruses are used. The data on NHP-derived adenoviral vectors obtained from vaccination studies can only partially support the suitability of NHP-derived adenoviruses for use in oncolytic virus therapy. In addition, the use of NHP-derived adenoviruses in humans might be received warily given the recent zoonotic infections with influenza viruses and coronaviruses. In this review, we discuss the similarities and differences between human- and NHP-derived adenoviruses in view of their use as oncolytic agents. These include their genome organization, receptor use, replication and cell lysis, modulation of the host’s immune responses, as well as their pathogenicity in humans. Together, the data should facilitate a rational and data-supported decision on the suitability of NHP-derived adenoviruses for prospective use in oncolytic virus therapy. View Full-Text
Keywords: non-human primate adenovirus; human adenovirus; oncolytic virus; adenoviral vector; taxonomy; genetic recombination; oncolysis; anti-tumor immunity non-human primate adenovirus; human adenovirus; oncolytic virus; adenoviral vector; taxonomy; genetic recombination; oncolysis; anti-tumor immunity
Show Figures

Graphical abstract

MDPI and ACS Style

Bots, S.T.F.; Hoeben, R.C. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents? Int. J. Mol. Sci. 2020, 21, 4821. https://doi.org/10.3390/ijms21144821

AMA Style

Bots STF, Hoeben RC. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents? International Journal of Molecular Sciences. 2020; 21(14):4821. https://doi.org/10.3390/ijms21144821

Chicago/Turabian Style

Bots, Selas T.F.; Hoeben, Rob C. 2020. "Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?" Int. J. Mol. Sci. 21, no. 14: 4821. https://doi.org/10.3390/ijms21144821

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop